Daniel Gesua Sive Salvadori - 25 Feb 2025 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Daniel Gesua Sive Salvadori by Jessica H. Paik, Attorney-in-Fact
Issuer symbol
ABT
Transactions as of
25 Feb 2025
Net transactions value
$0
Form type
4
Filing time
27 Feb 2025, 18:47:50 UTC
Previous filing
31 Jan 2025
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Award $0 +16,534 +13% $0.000000 142,231 25 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Award $0 +61,580 $0.000000 61,580 25 Feb 2025 Common Shares 61,580 $135.42 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes.
F2 Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 20,526 on February 25, 2026, 20,527 on February 25, 2027, and 20,527 on February 25, 2028.